DekaBank Deutsche Girozentrale
CNCE

DekaBank Deutsche Girozentrale’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,400
Closed -$46K – 1243
2019
Q3 		$46K Sell
7,400
-7,400
-50% -$78.5K ﹤0.01% 948
2019
Q2 		$174K Buy
14,800
+5,800
+64% +$62.4K ﹤0.01% 1033
2019
Q1 		$143K Buy
9,000
+1,600
+22% +$23.6K ﹤0.01% 1078
2018
Q4 		$88K Sell
7,400
-1,600
-18% -$22.1K ﹤0.01% 1077
2018
Q3 		$143K Hold
9,000
– – ﹤0.01% 1101
2018
Q2 		$154K Hold
9,000
– – ﹤0.01% 1071
2018
Q1 		$197K Buy
+9,000
New +$200K ﹤0.01% 992
2016
Q2 		– Sell
-9,600
Closed -$127K – 1061
2016
Q1 		$127K Sell
9,600
-1,500
-14% -$21.6K ﹤0.01% 923
2015
Q4 		$209K Buy
11,100
+200
+2% +$4.35K ﹤0.01% 859
2015
Q3 		$205K Buy
10,900
+400
+4% +$6.8K ﹤0.01% 863
2015
Q2 		$156K Buy
10,500
+1,100
+12% +$16.8K ﹤0.01% 953
2015
Q1 		$142K Buy
+9,400
New +$131K ﹤0.01% 962

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CNCE Position: Q4 2019 in Review

DekaBank Deutsche Girozentrale sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 7,400 shares — an estimated $46K sold.

DekaBank Deutsche Girozentrale first reported a position in CNCE in Q1 2015 and held it in 12 quarters. The position peaked at $209K in Q4 2015. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

  • DekaBank Deutsche Girozentrale reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 7,400 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $46K.
  • DekaBank Deutsche Girozentrale first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 12 quarters.
  • DekaBank Deutsche Girozentrale's Concert Pharmaceuticals, Inc. position peaked at $209K in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2019, filed 4 Feb 2020.